FDA guidance documents always stress they don’t give anybody any rights and don’t bind the agency to anything they say—instead, they merely represent the agency’s “current thinking” on a topic.
On the documents themselves, Janet Woodcock’s current thinking is that they’re too clunky. Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said the agency plans to tighten them up, at least for those addressing drug development for specific diseases.
“We’re going to try to not have our guidance documents be so long and not in prose but just encapsulate what the policy points that we wish to relay to the community are,” Woodcock mentioned during a panel discussion at this year’s Biopharma Congress, an event put on by Prevision Policy and Friends of Cancer Research.
She’s thinking bullet points, not dense text. And shorter explanations—two-pagers are possible, Woodcock told reporters after her appearance.
“What we’re trying to give them is the basic, bottom-line, salient points,” she said.
New guidance documents following this format are in the pipeline and undergoing internal review now, Woodcock said, although some already cleared to go out will largely follow the traditional format.
Woodcock wants to get a “stream” of concise guidance documents out that update current ones that are obsolete.
“It’s really sort of a streamlined message development that we can get out quickly so that we can have up-to-date standards for different disease areas,” she said.
New guidance documents will provide the basics, Woodcock said—what a development path should look like, what the end points should be, how many participants to include, for example.
The approach will be figuring out “what to tell them and just say it,” she said. “So that’s what we’re going to try to do. We’ll see.”
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)